Asset profile
agenT-797
Cell therapy
Evidence outlook · lead readout
NCT04754100 · Relapsed/Refractory Multiple Myeloma
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT04754100: This was a single-arm, open-label dose-escalation study with no control group and only 13 participants, designed to check safety rather than prove a treatment effect. No results have been posted, so nothing about how well the therapy worked can yet be assessed.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.